BRIUMVI J Code: J2329
Injection, ublituximab-xiiy, 1mg
Q4 2026 Medicare Payment Limit for J2329, effective October 1, 2026: $71.089 per HCPCS billing unit, down 1.6% from $72.239. From CMS's final file.
Drug & Product Overview
About BRIUMVI
Briumvi is a medication aligned to the HCPCS J Code: J2329 for billing, pricing, and reimbursement purposes in the United States. It is a Neurology drug administered via the intravenous route and manufactured by TG Therapeutics.
According to CMS Drug Use Information: This medication is used to treat multiple sclerosis (MS). Ublituximab is not a cure for MS but it is thought to help by preventing immune system cells (lymphocytes) from attacking the nerves in your brain and spinal cord. Ublituximab belongs to a class of drugs known as monoclonal antibodies. It helps decrease the number of episodes of disease worsening (relapses) and may prevent or delay disability.
Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.
NDC Code Information
Based on publicly available CMS files. The list of NDCs below is not exhaustive.
| NDC Code | Drug | Manufacturer | Billing Units / Pkg | Package Size |
|---|---|---|---|---|
| 73150-0150-06 | Briumvi | TG Therapeutics, Inc. | 150 | 150 MG / 6 ML |
BRIUMVI Pricing & Reimbursement
National median reimbursement across major commercial payers.
Create an account on PayerPrice for more information →Historical Graphing and Billing Calculator
Log in to calculate billing and reimbursement with live ASP, WAC & AWP pricing.
Login to use the calculator →BRIUMVI Claims Performance
Real-world claims performance from FocalPoint, OnPoint Oncology's reimbursement analytics platform, with claims data accrued at the clearing house level.
Explore J2329 claims analytics on FocalPoint →
BRIUMVI CPT Administration Codes
The below list of CPT codes is intended for informational purposes only and may not be exhaustive. CPT® codes and descriptions are copyright American Medical Association (AMA). All rights reserved.
| CPT Code | Description |
|---|---|
| 96413 | Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug |
| 96415 | Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure) |
CMS has identified Briumvi (J2329) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. Wastage billing guide →
BRIUMVI Clinical Information
Indications and drug classification.
This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.
Login for BuyandBill.com Analytics
Unlock deeper insights with BuyandBill’s Comparative Report!
- Compare ASP, WAC, and AWP across drugs.
- Visualize Drug Price Movement Over Time
- Tailor reports to drug class, manufacturer, or HCPCS Code.
- Compare Biosimilar and 505(b)(2) products.
Frequently Asked Questions
Is there an available Briumvi billing and coding guide?
Are there any available Briumvi patient assistance programs?
Where can I find Briumvi prescribing information?
Where can I find Briumvi side effect information?
Does billing BRIUMVI require JZ/JW wastage modifiers?
About BuyandBill.com:
The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.
Related Drug Codes
Explore billing, coding, and pricing for drugs related to BRIUMVI.